Related Experiment Videos
Altered eicosanoid levels in human colon cancer
B Rigas1, I S Goldman, L Levine
1Department of Medicine, Cornell University Medical College, New York, NY 10021.
The Journal of Laboratory and Clinical Medicine
|November 1, 1993
Summary
Eicosanoids like prostaglandin E2 (PGE2) are elevated in colon cancer, while prostacyclin (PGI2) is decreased. This suggests nonsteroidal anti-inflammatory drugs (NSAIDs) may protect against colon cancer by inhibiting eicosanoid synthesis.
Area of Science:
- Biochemistry
- Oncology
- Gastroenterology
Background:
- Eicosanoids, products of arachidonic acid metabolism, are implicated in colon carcinogenesis.
- Animal models and epidemiological studies suggest NSAIDs inhibit colon cancer development.
Purpose of the Study:
- To investigate the levels of specific eicosanoids in human colon cancer tissue compared to normal adjacent mucosa.
- To explore the relationship between eicosanoid levels and colon cancer progression.
Main Methods:
- Quantification of prostaglandin E2 (PGE2), PGF2 alpha, prostacyclin (PGI2), thromboxane A2 (TXA2), and leukotriene B4 (LTB4) in 21 pairs of human colon cancer and normal mucosa samples.
- Analysis of eicosanoid levels in relation to tumor stage (Dukes' stage).
Main Results:
- Prostaglandin E2 (PGE2) levels were significantly elevated in colon cancer tissues compared to normal tissues (p < 0.01).
- Prostacyclin (PGI2) levels were significantly decreased in colon cancer tissues (p < 0.05).
- No significant differences were observed for PGF2 alpha, TXA2, or LTB4; no association found with Dukes' stage.
Conclusions:
- Findings support the hypothesis that altered eicosanoid metabolism contributes to human colon cancer.
- The chemopreventive effects of aspirin and NSAIDs in colon cancer may be partly mediated by inhibiting cyclooxygenase-dependent arachidonic acid metabolism.